| 9.58 0.02 (0.21%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.32 | 1-year : | 14.9 |
| Resists | First : | 11.41 | Second : | 12.76 |
| Pivot price | 10.6  |
|||
| Supports | First : | 9.22 | Second : | 7.67 |
| MAs | MA(5) : | 9.65 |
MA(20) : | 10.92 |
| MA(100) : | 13.57 |
MA(250) : | 0 | |
| MACD | MACD : | -0.8 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 12.2 |
D(3) : | 9.9 |
| RSI | RSI(14): 29.7 |
|||
| 52-week | High : | 22.32 | Low : | 9.22 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LXEO ] has closed above bottom band by 16.9%. Bollinger Bands are 15.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.79 - 9.86 | 9.86 - 9.92 |
| Low: | 9.21 - 9.29 | 9.29 - 9.36 |
| Close: | 9.45 - 9.58 | 9.58 - 9.7 |
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Wed, 11 Sep 2024
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend Sells 5,000 Shares - MarketBeat
Mon, 12 Aug 2024
Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights - StockTitan
Fri, 12 Jul 2024
Lexeo Therapeutics CEO sells over $900k in company stock - Investing.com
Mon, 11 Mar 2024
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing - GlobeNewswire
Mon, 11 Dec 2023
Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights - Yahoo Finance
Sun, 12 Nov 2023
Richard Nolan Townsend Net Worth (2024) - GuruFocus.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 33 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 91.5 (%) |
| Shares Short | 1,240 (K) |
| Shares Short P.Month | 1,660 (K) |
| EPS | -12.53 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.98 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -40 % |
| Return on Equity (ttm) | -74.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -63 (M) |
| Levered Free Cash Flow | -37 (M) |
| PE Ratio | -0.77 |
| PEG Ratio | 0 |
| Price to Book value | 1.91 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.04 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|